To know more about Retinopathy of Prematurity, please click here.
This study, published in Ophthalmology, was to determine if (1) tortuosity assessment by a computer program (ROPtool, developed at the University of North Carolina, Chapel Hill, and Duke University, and licensed by FocusROP) that traces retinal blood vessels and (2) assessment by a lay reader are comparable with assessment by a panel of 3 retinopathy
READ MORE…
A team of researchers at the CHA University in South Korea has successfully transplanted mesenchymal stromal cells (MSCs) derived from human amniotic membranes of the placenta (AMSCs) into laboratory mice modeled with oxygen-induced retinopathy, which is used to simulate many retinal diseases. The treatment aimed at suppressing abnormal angiogenesis (blood vessel growth) which is recognized
READ MORE…
Extremely preterm infants (<28 weeks’ gestational age) have higher rates of adverse neurodevelopmental outcomes in early childhood than children born at term.
This trip was supported by Allergan Foundation, with instrument support from IRIDEX. Our CEO Dr Raj Agrawal made his second trip to Belize recently. This time, apart from seeing patients in Belize City, he also traveled to Orange Walk, which is an hour’s drive away from Belize City, as well as to Dangriga, which is
READ MORE…
This project has been made possible by a grant from Allergan Foundation. Driving to BCVI’s National Eye Clinic BCVI’s National Eye Clinic BCVI’s National Eye Clinic Belize City Pouring rain in Belize City An ROP baby being examined in the clinic Discussing the outcomes of the exam with the mother Discussing the outcomes of the
READ MORE…
Retinopathy of prematurity (ROP) continues to be an ongoing challenge for both ophthalmologists and neonatologists and remains a significant threat to vision for extremely premature infants despite the availability of therapeutic modalities. It remains a leading cause of morbidity despite, (and interestingly) as well as because of, advances in neonatal care, which have improved survival
READ MORE…